Show simple item record

dc.contributor.advisorGomez Polanía, Omar Leonardo 
dc.creatorMonroy Muñoz, Ricardo 
dc.date.accessioned2014-02-12T15:21:33Z
dc.date.available2014-02-12T15:21:33Z
dc.date.created2013-01-05
dc.date.issued2013 
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/4941
dc.descriptionIntroducción: Los desórdenes hipertensivos en el embarazo son la mayor causa de morbimortalidad materna en el mundo, su tratamiento habitualmente se realiza con nifedipino o enalapril durante el postparto indistintamente, pero no hay estudios que los comparen. Metodología: Se realizó un estudio de corte transversal con fines analíticos en el cual se incluyeron las historias clínicas de pacientes con trastorno hipertensivo durante el postparto que recibieron alguno de estos dos medicamentos y se evaluó el control de tensión arterial, necesidad de otros antihipertensivos, efectos adversos, presencia de complicaciones en ambos grupos. Resultados: Se estudió una muestra representativa, homogénea de 139 pacientes (p 0,43). Todas controlaron las cifras tensionales con el medicamento recibido. El 45% (n=62) recibió enalapril 20 mg cada 12 horas, el 40% (n=56) recibió nifedipino 30 mg cada 8 horas, el 15% (n=21) recibió nifedipino 30 mg cada 12 horas. No se presentaron efectos adversos, complicaciones o mortalidad en ninguno de los grupos. Las pacientes con enalapril requirieron más antihipertensivos comparado con las pacientes que recibieron nifedipino con diferencia estadísticamente significativa (p 0,001). Discusión La escogencia de un antihipertensivo durante el postparto debe estar encaminada al tipo de trastorno antihipertensivo: aquellos que se presentan por primera vez durante el embarazo se les administra nifedipino con excelentes resultados; aquellos con antecedente de hipertensión previa se les administra enalapril con buenos resultados. Ambos medicamentos controlaron la presión arterial adecuadamente sin complicaciones ni mortalidad.
dc.description.abstractIntroduction: Hypertensive disorders during pregnancy are a major cause of maternal morbidity and mortality worldwide, and its treatment postpartumis usually performed with nifedipine or enalapril interchangeably, but there are no studies that compare one with another. Methods: I conducted a cross sectional study with analytical purposes which included clinical records of patients with hypertensive disorder during the postpartum who received either of these two drugs and the variables to evaluate were blood pressure control, need for additional antihypertensive effects, presence of complications in both groups. Results : We studied a homogeneous sample of 139 patients ( p 0,43 ) . All the patients controlled the blood pressure with the medication received . The 45% (n = 62) received enalapril 20 mg bid, 40% ( n = 56 ) received nifedipine 30 mg tid, 15% (n = 21) received nifedipine 30 mg bid. There were no side effects, complications or mortality in either group . The patients receiving enalapril required more antihypertensive compared with patients who received nifedipine with statistically significant difference ( p 0.001 ) . Discussion The choice of an antihypertensive during postpartum should be directed depending on the type of hypertensive disorder: those presenting for the first time during pregnancy nifedipine is administered with excellent results, those with a history of previous hypertension enalapril is administered with good results. Both drugs controlled blood pressure adequately without complications or mortality.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectantihipertensivos
dc.subjecthipertensión durante postparto
dc.subjectnifedipino
dc.subjectenalapril
dc.titleEnalapril versus nifedipino para el manejo de la hipertensión arterial postparto
dc.typebachelorThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Ginecología y Obstericia
dc.publisher.programEspecialización en Ginecología y Obstericia
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordantihypertensive
dc.subject.keywordhypertension during postpartum
dc.subject.keywordnidepine
dc.subject.keywordenalapril
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsANTIHIPERTENSIVOS
dc.subject.decsENALAPRIL - ADMINISTRACIÓN & DOSIFICACIÓN
dc.subject.decsHIPERTENSIÓN EN EL EMBARAZO - TRATAMIENTO
dc.subject.decsNIFEDIPINO - ADMINISTRACIÓN & DOSIFICACIÓN
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitation1. Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J ObstetGynecol 2012 Jun;206(6):470-5.
dc.source.bibliographicCitation2. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308–315.
dc.source.bibliographicCitation3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJLJr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. TheSeventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension. 2003;42:1206 –1252.
dc.source.bibliographicCitation4. Magee LA, Helewa M, Moutquin JM, et al, for the Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada, Treatment of the hypertensive disorders of pregnancy. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J ObstetGynaecol Can 2008;30(3 Suppl 1):S24–36.
dc.source.bibliographicCitation5. National Collaborating Centre for Women’s and Children’s Health. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. London: National Institute for Health and Clinical Excellence (NICE); 2010. p. 46. (Clinical guideline; no. 107).
dc.source.bibliographicCitation6. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular disease during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(24):3147–97.
dc.source.bibliographicCitation7. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101:329-35.
dc.source.bibliographicCitation8. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002;100:369 –377.
dc.source.bibliographicCitation9. Weber MJ. Natural history of hypertension. J Hypertension. 2003;21(suppl 6):S37-S46.
dc.source.bibliographicCitation10. Abalos E, Duley L, Steyn D, Henderson-Smart D. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;CD002252.
dc.source.bibliographicCitation11. ACOG (2002). American College of Obstetricians and Gynecologists practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Int. J Gynaecol. Obstet. 77, 67-75.
dc.source.bibliographicCitation12. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: Clinical issues and management. BMC Pregnancy and Childbirth 2009, 9:8
dc.source.bibliographicCitation13. Sibai, B. M. (2004). Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet. Gynecol.103, 981-991
dc.source.bibliographicCitation14. Kaufmann, P., Black, S. and Huppertz, B. (2003). Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reprod. 69, 1-7.
dc.source.bibliographicCitation15. Roberts, J. M. and Hubel, C. A. (2009). The two stage model of preeclampsia: variations on the theme. Placenta 30 Suppl. A, S32-S37.
dc.source.bibliographicCitation16. Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E. et al. (2003). Excess placentalsolublefms-like tyrosine kinase 1 (sFlt1) maycontribute to endothelial dysfunction, hypertension,and proteinuria in preeclampsia. J. Clin. Invest. 111,649-658.
dc.source.bibliographicCitation17. Gadonski, G., LaMarca, B. B., Sullivan, E., Bennett, W., Chandler, D. and Granger, J. P. (2006). Hypertensionproduced by reductions in uterine perfusion in thepregnant rat: role of interleukin 6. Hypertension 48,711-716.
dc.source.bibliographicCitation18. Caniggia I. and Winter, J. L. (2002). Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies – a review. Placenta 23 Suppl. A, S47-S57.
dc.source.bibliographicCitation19. Robertson, S. A., Guerin, L. R., Bromfield, J. J., Branson, K. M., Ahlstrom, A. C. and Care, A. S. (2009). Seminal fluid drives expansion of theCD4+CD25+ T regulatory cell pool and inducestolerance to paternal alloantigens in mice. Biol.Reprod. 80, 1036-1045.
dc.source.bibliographicCitation20. Makris, A., Xu, B., Yu, B., Thornton, C. and Hennessy, A. (2006). Placental deficiency of interleukin-10 (IL-10)in preeclampsia and its relationship to an IL10promoter polymorphism. Placenta 27, 445-451.
dc.source.bibliographicCitation21. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. SeminNephrol. 2011;31:33– 46.
dc.source.bibliographicCitation22. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P. Angiogenic Factors in Superimposed Preeclampsia. A Longitudinal Study of Women With Chronic Hypertension During Pregnancy. Hypertension. 2012;59:740-746.
dc.source.bibliographicCitation23. Podymow T, August P. Update on the Use of Antihypertensive Drugs in Pregnancy. Hypertension 2008, 51:960-969
dc.source.bibliographicCitation24. Davis GK, Mackenzie C, Brown MA, Homer CS, Holt J, McHugh L, Mangos G. Predicting transformation from gestational hypertension to preeclampsia in clinical practice: a possible role for 24 hour ambulatory blood pressure monitoring. Hypertens Pregnancy. 2007;26:77– 87.
dc.source.bibliographicCitation25. Barton JR, O’Brien JM, Bergauer NK, Jacques DL, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol. 2001;184:979 –983
dc.source.bibliographicCitation26. Tan L, de Swiet M. The management of postpartum hypertension. BJOG 2002;109:733-6.
dc.source.bibliographicCitation27. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J ObstetGynecol 2000;183:S1-22
dc.source.bibliographicCitation28. Podymow T, Aujgust P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010;29:294-300.
dc.source.bibliographicCitation29. Ghuman N, Rhiener J, Tendler BE, White WB. Hypertension in the postpartum woman: clinical update for the hypertension specialist. J ClinHypertens (Greenwich) 2009;11:726-33.
dc.source.bibliographicCitation30. Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J ObstetGynecol 2004;190:577-8.
dc.source.bibliographicCitation31. Singhal AB, Bernstein RA. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Neurocrit Care 2005;3:91-7
dc.source.bibliographicCitation32. Berks D, Steegers EAP, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. ObstetGynecol 2009;114:1307-14.
dc.source.bibliographicCitation33. Magee L, Sadeghi S. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev 2005;1:CD004351.
dc.source.bibliographicCitation34. Ascarelli MH, Johnson V, McCreary H, Cushman J, May WL, Martin JN. Postpartum Preeclampsia Management With Furosemide: A Randomized Clinical Trial. ObstetGynecol 2005;105:29–33.
dc.source.bibliographicCitation35. Magee L, von Dadelszen P.Prevention and treatment of postpartum hypertension. The Cochrane Library 2013, Issue 4
dc.format.tipoDocumento
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/

 

Reconocimientos: